Future research should focus on identifying predictive biomarkers and evaluating combined approaches, including TRK inhibition and antiangiogenic therapy, to improve outcomes in patients with molecularly defined CRC, particularly those at risk for vascular complications such as PTTM. This evidence concerns the gene NTRK1 and colorectal carcinoma.